

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis

Jan Philipp Bewersdorf,¹ Smith Giri,² Rong Wang,^{3,4} Robert T. Williams,⁵ Martin S. Tallman,⁶ Amer M. Zeidan,^{1,4} and Maximilian Stahl⁶

¹Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT; ²Division of Hematology and Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL; ³Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT; ⁴Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, CT; ⁵Rockefeller University, New York, NY and ⁶Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Correspondence: MAXIMILIAN STAHL - stahlm@mskcc.org

doi:10.3324/haematol.2019.242826

Supplementary materials:

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: A systematic review and meta-analysis

Jan Philipp Bewersdorf¹, Smith Giri², Rong Wang,^{3,4} Robert T. Williams⁵, Martin S. Tallman⁶, Amer M. Zeidan^{1,4}, and Maximilian Stahl^{6*}

1. Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT
2. Division of Hematology and Oncology, University of Alabama School of Medicine
- 3: Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT.
- 4: Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, CT.
5. Rockefeller University, New York, NY
6. Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

*Corresponding Author: Maximilian Stahl. Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY. E-Mail: stahlm@mskcc.org

Supplementary Table 1: Modified Downs and Black checklist

Study (year of publication)	Reporting (items 1-10; max. 11 points)	External validity (items 11-13; max. 3 points)	Internal validity; bias (items 14-20; max. 7 points)	Internal validity; confounding (items 21-26; max. 6 points)	Power (item 27; max. 1 point)	Total
Konopoleva et al. (2016) (7)	9	3	5	2	1	20
Huemer et al. (2019) (8)	7	3	5	2	0	17
Aldoss et al. (2019) (11)	5	3	5	2	0	15
DiNardo et al. (2018) (6)	8	3	5	1	1	18
Ram et al. (2019) (10)	8	3	5	2	0	18
Goldberg et al. (2017) (5)	7	3	5	2	0	17
Shahswar et al. (2018) (12)	7	3	5	2	0	17

Supplementary Table 2: Description of baseline patient characteristics included in original studies

Author	Treatment	Median age	Median ECOG	ELN risk classification	Secondary AML (%)	IDH1/2-mut (%)	NPM1-mut (%)	FLT3-mut (%)	TP53-mut (%)	Median number of prior lines of therapy	Prior HMA (%)	Prior SCT (%)
Aldoss et al	VEN+DEC (81 patients), VEN + AZA (9 patients)	59	not documented	Favorable: 8% Intermediate: 26% Adverse: 66%	24	18	9	28	18	2	51	29
Konopoleva et al	VEN	71	1	not documented	54	38	13	13	not documented	not documented	75	13
DiNardo et al.	VEN+DEC (23 pts), VEN+AZA (8 pts), VEN+LDAC (8 pts), VEN+other (4 pts)	68	not documented	Favorable: 5% Intermediate: 49% Adverse: 47%	31	26	7	12	23	3	77	12
Goldberg et al	VEN+DEC (3 pts), VEN+AZA (4 pts), VEN+LDAC (16 pts)	66	not documented	Favorable: 10% Intermediate: 28% Adverse: 62%	58	not documented	not documented	not documented	not documented	3	76	29
Huemer et al	VEN	74	not documented	Not reported	100	29	not documented	not documented	not documented	1	100	0
Ram et al	VEN+DEC (4 pts), VEN+AZA (16 pts), VEN+LDAC (3 pts)	76	not documented	Favorable: 9% Intermediate: 48% Adverse: 43%	66	not documented	4	13	not documented	2	100	26

Shahswar et al	VEN+ DEC (1 pt), VEN+ AZA (5 pts), VEN+ LDAC (2 pts)	68	not documented	not reported	63	not documented	not documented	not documented	not documented	not documented	88	12
----------------	--	----	----------------	--------------	----	----------------	----------------	----------------	----------------	----------------	----	----